Abstract: The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough.

Abstract: Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (I) or a salt thereof.

Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

Abstract: Nefopam is used for the manufacture of a medicament for the treatment of an affective disorder such as ADD or ADHD.

Abstract: Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (1) or a salt thereof.

Abstract: A compound for therapeutic use, of the formula (I), wherein R1 is aryl or heteroaryl optionally substituted with R5; R2 is H, alkyl or CH2OH or forms part of a ring with R4; R3 is H, alkyl or CH2OH or forms part of a ring with R4; R4 is H, alkyl or (when forming part of a ring with R2 or R3) CH2; and R5 is alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2Me, CONH2, or SOMe; or a salt thereof.

Abstract: Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryi optionally substituted with one or more groups R6; R2 is alkyl or is part of a ring with R3; R3 is H, alkyl or CH2 (when forming part of a ring with R2); R4 is H or alkyl or is part of a ring with R5; R5 is aryl or heteroaryi optionally substituted with R7; each R6 is independently alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHSO2alkyl, CONH2, SOMe, SO2NH2, Salkyl, CH2SO2alkyl or OCONalkyl2; R7 is R8 or (CH2)nOR8, R9, CF3, OH, OR9, OCOR9, COR9, COOR9, CONH2, CH2CONH2, CN, halogen, NH2, NO2, NHCHO, NHCONH2, NHCONHR7, NHCON(R9)2, NHCOR9, NHCOaryl, NHSO2Me, CONH2, SMe, SOMe or SO2NH2; R8 is (CH2)nOR9, (CH)nOR9, (CH2)nCOOR9 or (CH2)nCOaryl; R9 is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof.

Abstract: A compound that is useful for the treatment or prevention of a condition such as pain, that is associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, is of formula (I) wherein R1 is aryl or heteroaryl optionally substituted with R5; R2 is H, alkyl or CH2OH and can be part of a ring with R4; R3 is H, alkyl or CH2OH and can be part of a ring with R4; R4 is H or alkyl or CH2 (when forming part of a ring with R2 or R3); and R5 is alkyl, CF3, OH, Oalkyl, OCOalkyl, CONH2, CN, F, Cl, Br, I, NH2, NHCHO, NHCONH2, NHSO2alkyl, CONH2, SOMe, CH2OH or OCONalkyl2; or a salt thereof.

Abstract: Nefopam or an analogue thereof is useful in the treatment of a syndrome characterized by chronic pain and fatigue.

Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

Abstract: Actarit or a salt thereof is useful for the treatment of inflammatory bowel disease.

Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

Abstract: A method of treating an inflammatory disease or an autoimmune disease in a subject, comprises the administration of mefloquine.

Abstract: An anthroquinone such as diacerein is useful for the treatment of renal conditions and conditions (such as SLE) which lead to renal damage.

Abstract: According to the subject invention, antimalarial drugs (including salts or isomers thereof) may be used to treat degenerative disease. Antimalarial drugs include mefloquine, the enantiomers of mefloquine, hydroxychloroquine, the enantiomers of hydroxychloroquine, chloroquine, primaquine and quinine, and also their metabolites.

Abstract: A method of treating an inflammatory disease or an autoimmune disease in a subject, comprises the administration of mefloquine.

Abstract: An anti-muscarinic agent and a calcium channel blocker are suitable for simultaneous, sequential or separate use in the treatment of a muscle tone disorder or a proliferative, inflammatory or secretory condition.

Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.

Abstract: The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.